About Ayman Kabakibi
Ayman Kabakibi is a chief operating officer & EVP, R&D at Allotera Therapeutics.
Ayman Kabakibi first appears on SEC filings in 2021.
Experience
This experience comes from Ayman Kabakibi's profile and from SEC filings. For roles taken from filings, the years are when the filings name Ayman Kabakibi in the role, so the role may have started earlier or lasted longer.
Allotera Therapeutics, Inc. Current
Chief Operating Officer & EVP, R&D
Chief Operating Officer, Executive Vice President of Research & Development (2018 – Present)
2018 – Present · St. Louis, MO
Develops donor-cell therapies for people with blood cancers.
OI
OxaluRx Inc.
Chief Scientific Officer
2018 – 2021
TT
Tallac Therapeutics
Co-Founder & Vice President of Biology
2018
SL
Solstice Biologics LLC
Executive Director, Head of Biology & Pharmacology
2013 – 2017
TI
Traversa Therapeutics, Inc
Head of Biology & Pharmacology
2010 – 2012
KI
Kalypsys Inc.
Head of Pharmacology
2004 – 2009
PF
Pfizer
Senior Scientist
2000 – 2004
MC
Monsanto Company
Research Scientist
1998 – 2000
HH
Harvard Medical School and Massachusetts General Hospital
Medical Technologist (Part time)
1992 – 1998
Key Colleagues at Startups
The people Ayman Kabakibi works with at each company, as listed on that company's latest Form D.
Allotera Therapeutics, Inc. · Form D/A, Jul 23, 2026
DD
Drew Dennison
Director
KL
Kevin Li
Director
NM
Natalie Mount
Director
ND
Niall O'Donnell
Director
Kumar Srinivasan
President & Chief Executive Officer, director
Matthew Cooper
Co-Founder & Chief Scientific Officer
BH
Bosun Hau
Director
PK
Peter Kiener
Chair
Cherry Thomas
Chief Medical Officer
BM
Bali Muralidhar
Director